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Abstract: Both pre-clinical studies and phase 1–2 clinical trials have provided strong support 
for the potential role of regional drug delivery in the management of epithelial ovarian cancer, 
a disease process whose major manifestations remain largely localized to the peritoneal cavity 
in the majority of individuals with this malignancy. The results of 3 phase 3 randomized trials 
have revealed the favorable impact of primary cisplatin-based intraperitoneal chemotherapy 
in women who initiate drug treatment with small-volume residual ovarian cancer following an 
attempt at optimal surgical cytoreduction. Concerns have been raised regarding the toxicity of 
regional treatment, particularly the side-effect proﬁ  le associated with cisplatin. One rational 
approach to improving the tolerability of intraperitoneal chemotherapy is to substitute carbopla-
tin for cisplatin. This review discusses the rationale for and data supporting regional treatment 
of epithelial ovarian cancer, and highlights the potential role for intraperitoneal carboplatin in 
this clinical setting.
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Due to its location in the peritoneal cavity,1,2 many have considered direct intraperitoneal 
delivery of anti-neoplastic agents a rational approach to the management of ovarian can-
cer. In fact, reports in the early days of the development of cytotoxic chemotherapeutic 
agents revealed the potential for this strategy to improve symptoms in this malignancy, 
particularly those associated with the accumulation of malignant ascites.3,4
Unfortunately, those initial experiences essentially failed to demonstrate superior 
efﬁ  cacy associated with regional drug administration, compared to systemic (intrave-
nous or oral) delivery, and the additional time and effort required made this a rather 
unattractive management option. Further, for certain drugs (eg, cytotoxic alkylating 
agents with vesicant properties), substantial local toxicity (eg, abdominal pain, adhe-
sion formation leading to bowel obstruction) could be added to the known existing 
side effects of a particular drug (eg, emesis, bone marrow suppression).5,6
“Dedrick model” of regional treatment 
of ovarian cancer
In the late 1970s, Robert Dedrick and his colleagues at the National Cancer Institute 
(Bethesda, MD, USA), published a landmark theoretical modeling study which 
predicted that for anti-neoplastic agents possessing particular biological properties 
there would be a major pharmacokinetic advantage for exposure of the drug to cancer 
present within the peritoneal cavity following regional delivery, compared to systemic 
administration of the same agent.7 These provocative data and subsequently conducted 
pre-clinical evaluations provided a strong impetus for clinical investigators to renew 
their interest in exploring the concept of intraperitoneal treatment in the management 
of ovarian cancer.Therapeutics and Clinical Risk Management 2009:5 162
Markman
Rational selection of anti-neoplastic 
agents for intraperitoneal 
chemotherapy
Based on both the preclinical experience and the results 
of early phase clinical trials a number of features can be 
identiﬁ  ed that would predict a particular anti-neoplastic 
drug might exhibit favorable properties if utilized via the 
intraperitoneal route.
First, it is critical that the agent is not a vesicant or major 
irritant, as it has been clearly noted the resulting inﬂ  ammation 
can cause considerable local pain and subsequent adhesion 
formation.5 This event may interfere with drug distribution 
throughout the cavity, negatively inﬂ  uencing the efﬁ  cacy of 
regional treatment. Further, in addition to the acute reversible 
effects, more serious toxicity can develop (eg, bowel 
obstruction leading to required surgical intervention).
Second, agents that are slowly removed from the 
peritoneal cavity and rapidly cleared from the systemic 
circulation will exhibit the greatest pharmacokinetic advan-
tage following regional delivery. In this regard, drugs that 
are rapidly and extensively metabolized into non-toxic 
metabolites during their ﬁ  rst-pass through the liver are par-
ticularly attractive for intraperitoneal administration, as it 
has long been recognized that drug uptake from the cavity 
is largely via the portal circulation.8,9
Third, preclinical data demonstrating that an agent is 
biologically active against the particular malignancy (eg, 
ovarian cancer), and that the activity can be substantially 
enhanced when the malignant cells are exposed to higher peak 
concentrations of drug, or for considerably longer periods of 
time (greater area-under-the concentration-versus-time curve 
[AUC]), than can safely be achieved following systemic 
delivery, provides a strong rationale for examining regional 
administration in the clinical setting.10
Phase 1 trials of intraperitoneal 
therapy in ovarian cancer
Over the last several decades, a rather large number of 
anti-neoplastic drugs have been examined for their safety 
and pharmacokinetic properties when delivered by the 
intraperitoneal route (Table 1).11 Importantly, the relative 
limited local toxicity associated with certain agents (including 
cisplatin and carboplatin) was conﬁ  rmed in these studies.11,12–18 
although this critically relevant ﬁ  nding was not universal 
(eg, pain associated with intraperitoneal doxorubicin).19
As predicted by the “Dedrick Model”, those drugs known 
to undergo extensive metabolism during their ﬁ  rst pass 
through the liver have been shown to possess the greatest 
pharmacokinetic advantage following intraperitoneal 
administration.11 However, data for agents with more 
modest differences between total or peak exposures of the 
peritoneal and systemic compartments to the biologically 
active anti-neoplastic agents (eg, 10- to 20-fold for cisplatin, 
carboplatin) are of considerable interest and potential 
clinical relevance because these concentrations are simply 
not realistically attainable within the systemic compartment 
due to production of severe side effects (eg, bone marrow 
suppression; renal toxicity and neurotoxicity).
Further, provocative pre-clinical data for the platinum 
agents had revealed that resistance to these drugs can 
actually be quite “relative”, and may conceivably be 
overcome by exposing tumor cells to only modestly higher 
(eg, 2- to 4-fold) concentrations of the drugs compared to that 
documented to be within the systemic compartment following 
standard systemic treatment.20 Unfortunately, extensive prior 
clinical experience has revealed that even “doubling the dose” 
and concentration of cisplatin (eg, 75 mg/m2 to 150 mg/m2) or 
carboplatin (AUC 6 to AUC 12), and administering multiple 
cycles of such a regimen, would unquestionably lead to 
unacceptable toxicity. However, these higher concentrations, 
as well as the increased peak levels and AUCs are theo-
retically rather easily achievable within the conﬁ  nes of the 
peritoneal cavity following regional administration of the 
platinum drugs.
Depth of drug penetration: 
the major limiting factor associated 
with regional chemotherapy
The early phase 1 clinical trials provided a strong rationale for 
further exploration of regional treatment of ovarian cancer. 
However, extensive pre-clinical experience suggested that 
despite the impressive pharmacokinetic advantage associated 
with regional therapy this management approach would ﬁ  nd 
Table 1 Pharmacokinetic advantage associated with intraperitoneal 
delivery of anti-neoplastic agents with known activity in ovarian 
cancer
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its greatest utility in the setting of small volume residual 
macroscopic cancer or microscopic disease only, due to 
the very limited ability of such drugs to penetrate into solid 
tissue.21–24
Such penetration was observed in several modeling 
systems to range from a few cell layers to 1 to 2 mm from 
the cell surface. Of note, in a series of studies speciﬁ  cally 
examining the penetration of cisplatin in a rat model, the 
relative advantage of exposure to platinum, associated with 
intraperitoneal compared to systemic delivery, was a maximum 
of approximately a millimeter from the cell surface.22
These data would indicate that patients with large volume 
residual ovarian cancer would be unlikely to beneﬁ  t from 
intraperitoneal delivery because the high concentrations of 
drugs measured within the cavity itself would not reach very 
deep into any residual tumor. However, one might also specu-
late that if a malignant mass lesion was substantially reduced 
in volume by exposure to biologically active systemic therapy 
regional drug delivery may be effective in subsequent courses 
against the smaller residual disease.25
Further, since it is known that platinum (both cisplatin and 
carboplatin) reaches the systemic compartment in essentially 
full concentrations following regional administration (largely 
due to the fact there is very limited metabolism of the 
agents within the liver), it is not unreasonable to consider 
the administration of a platinum drug intraperitoneally even 
in the setting of larger volume cancer.12–18 This conclusion 
follows from the hypothesis that there will be satisfactory 
concentrations of the drug reaching tumor by capillary ﬂ  ow, 
and with subsequent courses the smaller volume residual 
tumor may beneﬁ  t from substantially greater local exposure 
associated with the intraperitoneal drug instillation. Of 
course, this is a hypothesis that is testable in a randomized 
phase 3 clinical trial.
Phase 2 trial experience with 
intraperitoneal chemotherapy 
of ovarian cancer
Not surprisingly, due it its established role in the management 
of ovarian cancer, the majority of experience examining 
regional delivery of anti-neoplastic drug therapy in ovarian 
cancer has focused on the platinum agents, principally 
cisplatin.11,26 Further, most of the trials have been in the 
second-line setting, following primary platinum-based 
systemic chemotherapy.
These circumstances permit an interesting perspective, 
in that is it possible to inquire about the level of biological 
activity observed with regional platinum delivery, compared 
to that of an individual patient’s prior experience with 
intravenous platinum. One published study speciﬁ  cally 
examined this question and noted that tumors that had not 
previously exhibited tumor regression to the concentrations 
of platinum attainable with systemic therapy rarely responded 
to regional treatment (with activity documented at surgical 
reassessment).26 This was the case even if the patient had 
only very small volume residual cancer when the second-line 
cisplatin-based intraperitoneal treatment program was 
initiated.
Conversely, in patients whose cancers had achieved 
partial responses to prior platinum therapy, as many as 30% 
to 40% of such individuals were found to have attained a 
surgically documented complete response to intraperitoneal 
cisplatin. Of interest, these provocative data support the 
general concept that the high concentrations of platinum 
noted following regional treatment are able to overcome a 
modest level of existing resistance. However, unfortunately, 
the attainable concentrations are unable to inﬂ  uence major 
inherent platinum resistance.
Intraperitoneal carboplatin was also examined in several 
phase 2 trials in women with ovarian cancer in the second-
line setting.14,27–30 In fact, overall, the drug demonstrated 
measurable biological activity quite comparable to that 
seen with cisplatin. This observation is not surprising in 
view of the known equivalence of the two platinum agents 
in advanced ovarian cancer when delivered systemically at 
optimal doses.
One retrospective analysis examining a single institutional 
experience employing either intraperitoneal cisplatin or 
carboplatin-based chemotherapy in the second-line setting 
noted similar surgically deﬁ  ned objective response rates to 
the two strategies in individuals who initiated chemotherapy 
with microscopic residual disease.31 However, a lower 
response rate was observed with carboplatin in women with 
any residual macroscopic cancer when the regional treatment 
program was initiated.
This clinical experience was similar to one reported 
pre-clinical evaluation that suggested the amount of measur-
able platinum within macroscopic tumors was lower with 
carboplatin than cisplatin following regional administration,32 
but it is important to note these data have not been conﬁ  rmed 
in any other pre-clinical model, or clinical experience with 
the two platinum strategies. Further, there have been no phase 
3 randomized trials in the second-line setting to conﬁ  rm 
(or refute) the utility of regional drug delivery with either 
cisplatin or carboplatin (or any other agent) in this patient 
population.Therapeutics and Clinical Risk Management 2009:5 164
Markman
Intraperitoneal carboplatin has also been examined in the 
phase 2 setting as a component of primary chemotherapy of 
advanced ovarian cancer.14,33,34 These non-randomized studies 
demonstrate the feasibility of the approach, and interesting 
survival data have been reported. What is missing are phase 
3 trial data employing the agent in this manner.
Phase 3 trials of cisplatin-based 
primary chemotherapy of small 
volume residual advanced 
ovarian cancer
Several phase 3 randomized trials have now been reported 
that explored the clinical utility of regional cisplatin chemo-
therapy employed as primary chemotherapy of small volume 
residual advanced ovarian cancer following an attempt at 
maximal cytoreductive surgery.35–37 Three of these studies 
were of sufﬁ  cient sample size and design to potentially 
provide deﬁ  nitive answers to the question of the utility of 
regional cisplatin in this setting (Table 2).
The ﬁ  rst trial, conducted by the Southwest Oncology 
Group (SWOG) and the Gynecologic Oncology Group 
(GOG) compared the same dose (100 mg/m2) of either intra-
peritoneal or intravenous cisplatin.35 All patients entered into 
this study also received intravenous cyclophosphamide. The 
largest residual tumor mass size permitted entry into this trial 
was 20 mm. Patients randomized to the intraperitoneal study 
arm experienced more abdominal discomfort (generally mild 
to moderate in severity), but no increase in severe clinical 
toxicity or treatment-related deaths. Further, there was a 
reduced incidence of neutropenia and tinnitus associated 
with local drug delivery. Of greatest importance, the study 
revealed a statistically signiﬁ  cant improvement in overall 
survival associated with regional delivery of cisplatin in this 
clinical setting (Table 2).
A second primary ovarian cancer regional chemotherapy 
trial was then conducted by the GOG and SWOG, with 
the addition of the Eastern Cooperative Oncology Group 
(ECOG) which again compared intraperitoneal cisplatin 
to intravenous cisplatin, but in this study all patients also 
received intravenous paclitaxel, rather than intravenous 
cyclophosphamide.36 Of note, the largest size of a residual 
mass lesion permitted entry into this trial was 10 mm.
This study added another novel component, based on 
the previously stated belief that regional drug delivery 
would be most relevant in those patients with the smallest 
residual tumor volumes. Thus, prior to the administration 
of regional chemotherapy, patients randomized to this study 
arm received 2 cycles of “moderately high dose” intravenous 
carboplatin (AUC 9) designed to “chemically debulk” any 
residual macroscopic cancer remaining after the initial 
cytoreductive surgery.38
Unfortunately, the two courses of intravenous carboplatin 
produced an unexpectedly high incidence of severe 
thrombocytopenia, such that 19% of patients received two or 
fewer courses of intraperitoneal drug delivery. This outcome 
was a direct result of carboplatin-associated bone marrow 
suppression and not local toxic effects of the regional treat-
ment program. Despite this fact, this study revealed improved 
progression-free survival and a borderline improvement 
in overall survival in the experimental regional treatment 
program, compared to the all-intravenous therapeutic 
regimen (Table 2).
The most recently reported randomized ovarian 
cancer regional chemotherapy study again compared 
intravenous to intraperitoneal cisplatin, but patients in 
the intraperitoneal chemotherapy arm were also administered 
intraperitoneal paclitaxel.37 All patients in the trial received 
intravenous paclitaxel. As with the previously discussed 
study, the largest size of any residual mass permitted entry 
into this trial was 10 mm. This study revealed a statistically 
signiﬁ  cant 16-month median improvement in overall survival 
associated with the regional therapy program, in addition to a 
documented improvement in progression-free survival.
Table 2 Phase 3 randomized trials comparing intraperitoneal (ip) versus intravenous (iv) cisplatin-based drug delivery employed as 
primary chemotherapy of small-volume residual advanced epithelial ovarian cancer
Progression-free survival (median) Overall survival (median)
ip versus iv cisplatin (all patients also received 
iv cyclophosphamide)35
– 48 vs 41 months (p = 0.02; HR 0.76)
ip versus iv cisplatina (all patients also received 
iv paclitaxel)36
28 vs 22 months (p = 0.01; HR 0.78) 63 vs 52 months (p = 0.05; HR 0.81)
ip versus iv cisplatinb (all patients also received 
iv paclitaxel)37
23.8 vs 18.3 months (p = 0.05; HR 0.77) 65.6 vs 49.7 months (p = 0.03; HR 0.73)
aPatients in the ip treatment arm also received two cycles of moderately high dose iv carboplatin prior to the delivery of regional chemotherapy.
bPatients in the ip treatment arm received ip paclitaxel in addition to ip cisplatin.Therapeutics and Clinical Risk Management 2009:5 165
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The intraperitoneal regimen was found to cause more 
toxicity and less than one half of the treated patient population 
was able to complete the entire planned 6 treatment cycles. Of 
interest, this study included a prospective evaluation of mea-
sures of quality of life. This analysis revealed inferior quality 
of life associated with the regional program during therapy, 
but importantly at 1-year follow-up there was essentially no 
difference between the two study arms.
One highly provocative question resulting from this third 
randomized trial is the issue of whether the documented 
improvement in overall survival observed following 
intraperitoneal drug delivery might have been even greater 
if a higher percentage of women had been able to receive 
the entire planned 6 treatment courses. Alternatively, it could 
be argued that the majority of the beneﬁ  ts achieved from 
regional platinum delivery may be observed if women are 
administered only 3 or 4 such cycles. Again, these questions 
remain interesting hypotheses that may be tested in future 
phase 3 randomized trials.
Rational use of intraperitoneal 
chemotherapy in epithelial 
ovarian cancer
Based on existing data, where is it appropriate to consider 
the use of intraperitoneal chemotherapy in the routine 
management of ovarian cancer?
Existing evidence-based (randomized phase 3 trial) data 
provide strong support for the conclusion that patients with 
small volume residual advanced ovarian cancer (largest 
tumor mass 10 mm in maximum diameter) should be 
offered the option to receive a cisplatin-based intraperitoneal 
strategy, assuming there are no medical contraindications 
to receiving cisplatin (eg, renal insufﬁ  ciency; pre-existing 
neuropathy) or to receiving regional treatment (eg, presence 
of extensive adhesions at the time of prior surgery).35–37,39,40 
Further, while a patient can certainly elect to not receive this 
treatment, based on the time, effort, and potential additional 
morbidity associated with the approach, it can also be argued 
that oncologists whose particular practice setting prevents 
their being able to offer such therapy should consider referral 
(where feasible) of an ovarian cancer patient who may beneﬁ  t 
from intraperitoneal drug delivery to an oncology practice 
where this strategy can be administered.
Intraperitoneal chemotherapy may also be rationally 
offered to women with advanced ovarian cancer who have 
been managed primarily with a neoadjuvant approach, but 
where an initial excellent response to chemotherapy has led to 
surgery and no or minimal residual tumor volume following 
the completion of this interval cytoreductive procedure.41 
Here one can argue that the high local concentrations 
achievable with intraperitoneal treatment may potentiate 
the effects of the chemotherapeutic agents already docu-
mented to be highly biologically active in the particular 
individual’s cancer. The ultimate beneﬁ  ts of this approach 
compared to the continuation of systemic chemotherapy is 
worthy of investigation in a phase 3 randomized trial. Of 
note, such a trial is currently planned to be conducted by the 
Gynecologic Cancer Intergroup, an international consortium 
of gynecologic cancer clinical investigators.
Intraperitoneal anti-neoplastic drug delivery may also be 
considered in the setting of an ovarian cancer patient with a 
high grade malignancy who has achieved a surgically deﬁ  ned 
complete response to primary systemic chemotherapy, where 
it is known the ultimate risk of recurrence is very high. 
While interesting phase 2 trial data supporting this approach 
have been presented,42 the few very underpowered phase 3 
trials that were designed to evaluate this approach have not 
provided evidence for the utility of this form of consolida-
tion therapy.43
Based on the results of the previously noted non-randomized 
phase 2 trials examining platinum-based second-line therapy 
in ovarian cancer, it is not unreasonable to consider this strat-
egy in a woman who has achieved a major partial response 
following primary systemic platinum chemotherapy.11,44–46 
However, again, no randomized phase 3 trial data are avail-
able to demonstrate the superiority of this approach compared 
to continuation of systemic therapy.
Finally, as it is known that patients with “high risk” 
early stage ovarian cancer have a 30% to 50% chance of 
experiencing recurrence of the disease process, and those 
recurrences are largely within the peritoneal cavity, it is 
perhaps reasonable to consider delivering some, or perhaps 
all, of a planned adjuvant chemotherapy approach via the 
intraperitoneal route. As previously stated, the administration 
of either intraperitoneal cisplatin or carboplatin will lead to 
adequate systemic drug concentrations, and also substantially 
higher platinum concentrations within the peritoneal cavity.
A role for intraperitoneal 
carboplatin
As outlined within this text, the large majority of currently 
reported trials examining regional drug delivery in ovarian 
cancer have employed cisplatin, rather then carboplatin. This 
is largely due to the fact the early studies of intraperitoneal 
chemotherapy were initiated before the widespread use of 
carboplatin, and subsequent evidence of the equivalence Therapeutics and Clinical Risk Management 2009:5 166
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of the two platinum drugs when delivered systemically in 
advanced ovarian cancer.
Is it reasonable to simply substitute carboplatin in any 
regimen where cisplatin has been utilized?
Extensive experience with systemically administered 
carboplatin in ovarian cancer has revealed the two agents 
have essentially equivalent biological activity, but with 
quite different toxicity proﬁ  les.47–49 The modestly reduced 
potential for the development of neuropathy associated with 
carboplatin, compared to cisplatin, is particularly relevant 
when the platinum agent is combined with another neurotoxic 
drug, such as a taxane. A “carboplatin plus paclitaxel” che-
motherapy regimen is easily administered in the out-patient 
setting, and this program continues to be an overwhelmingly 
favorite primary strategy among oncologists treating women 
systemically for ovarian cancer.
As previously noted, phase 2 trials of intraperitoneal 
carboplatin in ovarian cancer have reported favorable 
survival and toxicity outcomes, but there remains a notable 
absence of randomized phase 3 trial data employing the 
newer platinum drug delivered by this route. The GOG plans 
to examine intraperitoneal carboplatin in a phase 3 trial in 
the future, but it is unknown at this point in time when data 
from this experience will be available.
For the present, it is reasonable to consider several options 
when contemplating the use of intraperitoneal carboplatin in 
ovarian cancer:50,51
1.  Substitution of carboplatin for cisplatin in all patients 
receiving intraperitoneal chemotherapy:
While certainly not an irrational option, if an oncologist 
elects to simply substitute carboplatin for cisplatin, for 
example in a patient with small volume residual advanced 
ovarian cancer after primary surgical cytoreduction, it is 
incumbent upon the physician to inform the patient that 
the evidence-based studies that documented the utility of 
regional therapy actually employed cisplatin. Further, the 
speciﬁ  c justiﬁ  cation for utilizing carboplatin, rather than 
cisplatin, should be explained to the patient.
2.  Substitution of carboplatin if excessive toxicity with 
cisplatin is observed:
In this situation, the physician will attempt to initially 
deliver intraperitoneal cisplatin but if the patient experi-
ences excessive side effects (eg, emesis), the next course 
can be administered with intraperitoneal carboplatin. 
One can rationally argue that if the choice is between 
switching therapy to either intravenous carboplatin or 
intraperitoneal carboplatin, there is no reason to believe 
regional carboplatin delivery will be less effective, and 
it may be more effective than systemic administration 
of the agent.
3.  Plan to deliver a limited number of courses of both 
intraperitoneal cisplatin and carboplatin:
This strategy recognizes the fact it is difﬁ  cult for the 
majority of patients to tolerate 6 cycles of a cisplatin-
based intraperitoneal chemotherapy program, despite the 
fact the data demonstrating a survival beneﬁ  t were based 
on delivery of this agent. Thus, it might be planned that 
a woman with small volume residual advanced ovarian 
cancer will be treated with 2 to 3 cycles of intraperitoneal 
cisplatin (depending on tolerability), and then switched 
to intraperitoneal carboplatin (3–4 cycles) to complete 
the treatment program.
The optimal dose of intraperitoneal carboplatin also 
remains to be deﬁ  ned, but on the basis of existing data (both 
systemic and regional) it is rational to propose delivering the 
agent by this route at an AUC (area-under-the-concentration-
versus-time curve) of 5 or 6.14,47–51
Conclusion
The intraperitoneal delivery of cisplatin has been demon-
strated in several evidence-based randomized phase 3 trials 
to improve overall survival when employed as ﬁ  rst-line che-
motherapy treatment of women with small volume residual 
advanced ovarian cancer. Despite this fact, many oncologists 
remain reluctant to routinely employ this approach, often 
because of the well-recognized systemic toxicity associated 
with cisplatin.
The use of intraperitoneal carboplatin has a particular 
appeal in this setting, as the drug is well established as the 
primary platinum agent employed in the management of 
women with ovarian cancer, and it has been documented to 
have a more favorable toxicity proﬁ  le compared to the older 
platinum. Another very pragmatic attraction of intraperitoneal 
carboplatin is that use of the agent makes it easier to deliver 
regional therapy in the setting of a busy oncology practice 
(eg, less actual required treatment time; reduced risk of 
troublesome toxicities). Unfortunately, there remain no phase 
3 trial data documenting the equivalence of intraperitoneal 
cisplatin and carboplatin, or the superiority of intraperitoneal 
carboplatin compared to intravenous carboplatin.
Planned trials will hopefully provide deﬁ  nitive answers to 
this important question. For the present, it is not unreasonable 
to employ intraperitoneal carboplatin in the management of 
ovarian cancer after considering the limitations of existing 
data, and the potential toxicity of cisplatin-based therapy that 
may be, or has been, encountered in an individual patient.Therapeutics and Clinical Risk Management 2009:5 167
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